MarketInOut Stock Screener Log In | Sign Up
 

Annovis Bio Inc

NYSE • Healthcare • Biotechnology • Quote as of 10/16/2026 16:00
Annovis Bio Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNYSE
Market Capitalization45.24 mln
Float37.64 mln
Earnings Date11/11/2026

Piotroski F-Score

3 / 9
Below average

1-Year Forecast

10.50
Transformational upside

Relative Strength

16 / 100
Significantly lagging

ROE

-525
Deeply negative

ROA

-253
Deeply negative

Business Description

Annovis Bio is a Pennsylvania-based medical research company focused on developing treatments for brain diseases such as Alzheimer's, Parkinson's, and dementia. Its most advanced drug, Buntanetap, is currently being tested in late-stage clinical trials for both Alzheimer's and Parkinson's disease. The company also has two other drug candidates at various stages of testing, targeting traumatic brain injury, stroke, and cognitive decline. Founded in 2008, Annovis Bio continues to build a pipeline aimed at slowing or reversing the progression of neurological conditions.

Key Fundamentals

EPS-1.68
ROE-525
ROIC-5,547
ROA-253
Interest Cover-31.16
EBITDA, mln-49.52
EV / EBITDA-0.55
EV / EBIT-0.55

Quote Details

Last 0.9934
Change -0.0566 (-5.39%)
Open 1.06
Volume 641,422
Turnover 637,189
Average Volume 764,332

Financial Strength

Piotroski F-Score 3 / 9
1-Year Target Price10.50
Short Ratio4.29
Short % of Float15.66

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -17.9% 8 / 100   
1 Month -9.69% 37 / 100   
2 Months -43.56% 10 / 100   
6 Months -46.88% 15 / 100   
1 Year -45.12% 21 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us